Medicure Announces Positive Preclinical Results for MC-1

Medicure has reported that results from a preclinical in vivo study have shown potential for MC-1 in the treatment of hypertriglyceridemia.

Hypertriglyceridemia is commonly associated with metabolic disorders such as Type 2 diabetes, metabolic syndrome, insulin resistance and obesity. The triglyceride-lowering effects of MC-1 were evaluated in an industry-standard cholesterol model.

The in-vivo model involves feeding a high cholesterol diet to the subject animals thereby inducing high levels of triglycerides, total cholesterol and LDL cholesterol. Treatment with MC-1 (10 mg/kg) for seven weeks was associated with a 72 percent reduction in triglyceride levels versus control. In addition to the significant improvement shown relative to placebo, MC-1 also demonstrated an improvement versus an approved, widely prescribed triglyceride reduction agent in this model.